Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS 4: Oral Semaglutide 25 mg for Weight Management
NCT05564117Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2022
- Primary completion
- Apr 2024
- Countries
- 4
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Novo Nordisk. Started Oct 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05564117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564117.